{"mainPropery":{"diseaseId":10439,"diseaseName":"Hidradenocarcinoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/10439/hidradenocarcinoma","synonyms":["Malignant nodular/clear cell hidradenoma","Malignant acrospiroma","Malignant clear cell acrospiroma","Clear cell eccrine carcinoma","Primary mucoepidermoid cutaneous carcinoma"],"synonyms-with-source":[{"name":"Malignant nodular/clear cell hidradenoma","source":"Avraham JB et al., 2013 PubMed PMID: 23677677 "},{"name":"Malignant acrospiroma","source":"Avraham JB et al., 2013 PubMed PMID: 23677677 "},{"name":"Malignant clear cell acrospiroma","source":"Avraham JB et al., 2013 PubMed PMID: 23677677 "},{"name":"Clear cell eccrine carcinoma","source":"Avraham JB et al., 2013 PubMed PMID: 23677677"},{"name":"Primary mucoepidermoid cutaneous carcinoma","source":"Avraham JB et al., 2013 PubMed PMID: 23677677 "}],"identifiers":[{"identifierType":"UMLS","identifierId":"C0334344"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":120,"resourceName":"American Cancer Society","abbreviation":"","address1":"250 Williams Street NW","address2":"","address3":"","address4":"","address5":"","city":"Atlanta","state":"GA","zip":"30329","country":"United States","phone":"","tty":"","tollFree":"1-800-227-2345","fax":"","email":"","url":"https://www.cancer.org","freeText":""},{"resourceID":231,"resourceName":"Rare Cancer Alliance","abbreviation":"","address1":"1649 North Pacana Way","address2":"","address3":"","address4":"","address5":"","city":"Green Valley","state":"AZ","zip":"85614","country":"United States","phone":"520-625-5495 ","tty":"","tollFree":"","fax":"","email":"","url":"http://www.rare-cancer.org","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=Hidradenocarcinoma%5BAll+Fields%5D+AND+%22humans%22%5BMeSH+Terms%5D' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Hidradenocarcinoma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1101796-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:5570' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":3743,"questionText":"What is hidradenocarcinoma?","answerText":"<strong>Hidradenocarcinoma</strong> is a rare tumor caused by the abnormal growth of <a href=\"http://ghr.nlm.nih.gov/handbook/basics/cell\" target=\"_blank\">cells</a>  in a <a href=\"https://medlineplus.gov/ency/article/003218.htm\" target=\"_blank\">sweat gland</a>.&nbsp; It is a type of <a href=\"https://medlineplus.gov/cancer.html\" target=\"_blank\">cancer</a> that usually begins as a single spot (<a href=\"http://www.cancer.gov/dictionary/?CdrID=46324\" target=\"_blank\">lesion</a>) on the skin of the head or neck, but can be been found on other parts of the body. This type of tumor most often develops in people between the ages of 30-60 years old, but has been found in children. &nbsp;Hidradenocarcinoma is usually painless and tends to grow slowly, but may spread into nearby tissues, especially <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=45762\" target=\"_blank\">lymph nodes</a>, or to more distant parts of the body (<a href=\"http://www.cancer.gov/dictionary/?CdrID=46710\" target=\"_blank\">metastasis</a>). The cause of the tumor is unknown. Diagnosis is usually made by careful examination  and a series of special skin tests. The main treatment is surgical removal of the tumor often followed by <a href=\"https://medlineplus.gov/ency/article/001918.htm\" target=\"_blank\">radiation therapy</a> and/or <a href=\"https://medlineplus.gov/cancerchemotherapy.html\" target=\"_blank\">chemotherapy</a>. Long term outlook is best when the cancer is found early.[12092][12093]","dateModified":"2016-08-24T00:00:00"},"basicQuestions":[{"questionId":10998,"questionText":"What causes hidradenocarcinoma?","answerText":"The cause of hidradenocarcinoma is unknown. &nbsp;The only known risk factor is the prior presence of a&nbsp;<a href=\"http://www.dermnetnz.org/topics/sweat-gland-lesions/\" target=\"_blank\">benign hidradenoma</a>. &nbsp;Molecular genetic changes in the <a href=\"http://ghr.nlm.nih.gov/handbook/basics/cell\" target=\"_blank\">cells</a>  of the hidradenocarcinoma have been found in some cases, but more studies must be performed before medical researchers can determine if a pattern exists.[12092][12093][12094][12095][12096]&nbsp;<br />\r\n<br />\r\n<em>Please note, molecular genetic changes are also called&nbsp;<a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=46586\" target=\"_blank\">somatic mutations</a>&nbsp;or acquired mutations. &nbsp;You are not born with an acquired mutation, instead the change happens some time&nbsp;during&nbsp;your life. This change in the <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a>  occurs in one cell, and then is passed on to any new cells that are the offspring of that cell. This&nbsp;kind of <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a>  cannot be passed&nbsp;on to your children. Acquired mutations are much more common than inherited&nbsp;mutations. Most cancers are caused by acquired mutations.[12097]&nbsp;</em>","dateModified":"2016-08-24T21:47:00","resourceClassificationName":"Cause","references":[{"referenceId":12092,"authors":"","articleTitle":"Hidradenocarcinoma of Skin","bookWebsiteJournalTitle":"DoveMed","date":"January 7 2016","volume":"","pages":"","url":"http://www.dovemed.com/diseases-conditions/hidradenocarcinoma-skin","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12093,"authors":"Soni A, Bansal N, Kaushal V, and Chauhan AK","articleTitle":"Current management approach to hidradenocarcinoma: a comprehensive review of the literature","bookWebsiteJournalTitle":"Ecancermedicalscience","date":"March 19 2015","volume":"9","pages":"517","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370612","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12094,"authors":"Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, and Joseph RW","articleTitle":"Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature","bookWebsiteJournalTitle":"Rare Tumors","date":"February 25 2015","volume":"7(1)","pages":"5719","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387361","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12095,"authors":"Kazakov DV1, Ivan D, Kutzner H, Spagnolo DV, Grossmann P, Vanecek T, Sima R, Kacerovska D, Shelekhova KV, Denisjuk N, Hillen U, Kuroda N, Mukensnabl P, Danis D, and Michal M","articleTitle":"Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation","bookWebsiteJournalTitle":"Am J Dermatopathol","date":"May 2009","volume":"31(30","pages":"236-47","url":"https://www.ncbi.nlm.nih.gov/pubmed/19384064","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12096,"authors":"Nash JW1, Barrett TL, Kies M, Ross MI, Sneige N, Diwan AH, and Lazar AJ","articleTitle":"Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications","bookWebsiteJournalTitle":"J Cutan Pathol","date":"January 2007","volume":"34(1)","pages":"49-54","url":"https://www.ncbi.nlm.nih.gov/pubmed/17214855","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12097,"authors":"","articleTitle":"Genes and Cancer","bookWebsiteJournalTitle":"American Cancer Society","date":"June 2014","volume":"","pages":"","url":"http://www.cancer.org/acs/groups/cid/documents/webcontent/002550-pdf.pdf","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10999,"questionText":"How is&nbsp;hidradenocarcinoma inherited?","answerText":"Medical researchers have not found any genetic change which a person is born with that may increase their risk for developing&nbsp;hidradenocarcinoma nor are there any reports in the literature which suggest this rare cancer runs in families.[12092][12093][12094]","dateModified":"2016-08-24T22:06:00","resourceClassificationName":"Inheritance","references":[{"referenceId":12092,"authors":"","articleTitle":"Hidradenocarcinoma of Skin","bookWebsiteJournalTitle":"DoveMed","date":"January 7 2016","volume":"","pages":"","url":"http://www.dovemed.com/diseases-conditions/hidradenocarcinoma-skin","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12093,"authors":"Soni A, Bansal N, Kaushal V, and Chauhan AK","articleTitle":"Current management approach to hidradenocarcinoma: a comprehensive review of the literature","bookWebsiteJournalTitle":"Ecancermedicalscience","date":"March 19 2015","volume":"9","pages":"517","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370612","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12094,"authors":"Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, and Joseph RW","articleTitle":"Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature","bookWebsiteJournalTitle":"Rare Tumors","date":"February 25 2015","volume":"7(1)","pages":"5719","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387361","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":5663,"questionText":"How might hidradenocarcinoma be treated?","answerText":"Because hidradenocarcinoma is quite rare, there are no established guidelines for treatment. &nbsp; The most accepted form of treatment is <a href=\"http://www.cancer.gov/dictionary?CdrID=446983\" target=\"_blank\">wide local excision</a>&nbsp;of the tumor, but due to the high risk that the tumor will grow back and frequent <a href=\"http://www.cancer.gov/types/metastatic-cancer\" target=\"_blank\">metastasis</a> to nearby <a href=\"http://www.cancer.gov/dictionary?CdrID=45762\" target=\"_blank\">lymph nodes</a> and other parts of the body, some doctors also suggest&nbsp;<a href=\"https://medlineplus.gov/radiationtherapy.html\" target=\"_blank\">radiation therapy</a> and/or&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/cancerchemotherapy.html\" target=\"_blank\">chemotherapy</a>&nbsp;after surgery.[12092][12093] &nbsp; <br />\r\n<br />\r\nNewer targeted therapies like&nbsp;<a href=\"http://www.cancer.gov/about-cancer/treatment/drugs/trastuzumab\" target=\"_blank\">trastuzumab</a>,&nbsp;<a href=\"https://www.drugs.com/drug-class/egfr-inhibitors.html\" target=\"_blank\">epidermal growth factor receptor (EGFR) inhibitors</a>, PI3K/Akt/mTOR pathway inhibitors (targets a pathway believed to be involved in controlling cell growth and division), hormonal agents like&nbsp;<a href=\"http://www.dermnetnz.org/topics/anti-androgen-therapy/\" target=\"_blank\">antiandrogens</a>, and electrochemotherapy (the use of electrical pulses to help get the chemo drugs into the cancer cells) may also be offered. &nbsp;Most of these therapies have only been reported in isolated case reports and often with conflicting results. Therefore it is difficult to determine which therapy or combination of therapies are the best treatment option. Options are usually determined by the size and location of the cancer and the extent to which cancer cells may have spread to nearby tissues.. &nbsp;Many researchers are hoping if there is a better understanding of the molecular genetic changes which happen in the cells of hidradenocarcinoma, the use of targeted therapies will improve long term prognosis.[12092][12093] &nbsp;","dateModified":"2016-08-24T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":12092,"authors":"","articleTitle":"Hidradenocarcinoma of Skin","bookWebsiteJournalTitle":"DoveMed","date":"January 7 2016","volume":"","pages":"","url":"http://www.dovemed.com/diseases-conditions/hidradenocarcinoma-skin","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12093,"authors":"Soni A, Bansal N, Kaushal V, and Chauhan AK","articleTitle":"Current management approach to hidradenocarcinoma: a comprehensive review of the literature","bookWebsiteJournalTitle":"Ecancermedicalscience","date":"March 19 2015","volume":"9","pages":"517","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370612","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":3762,"questionText":"How common is hidradenocarcinoma?","answerText":"Hidradenocarcinoma is very rare. Cancerous tumors which begin in the major sweat glands (eccrine carcinomas) make up less that 0.01% of all skin cancers. Hidradenocarcinoma accounts for approximately 6% of cancerous eccrine tumors and less than 0.001% of all tumors.[12093] [2629]<br />\r\n<br />","dateModified":"2016-08-24T00:00:00","resourceClassificationName":"Statistics","references":[{"referenceId":2629,"authors":"Gauerke S, Driscoll JJ","articleTitle":"Hidradenocarcinomas: A Brief Review and Future Directions","bookWebsiteJournalTitle":"Archives of Pathology and Laboratory Medicine","date":"May 2010","volume":"134(5)","pages":"781-5","url":"https://www.ncbi.nlm.nih.gov/pubmed/20441512","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12093,"authors":"Soni A, Bansal N, Kaushal V, and Chauhan AK","articleTitle":"Current management approach to hidradenocarcinoma: a comprehensive review of the literature","bookWebsiteJournalTitle":"Ecancermedicalscience","date":"March 19 2015","volume":"9","pages":"517","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370612","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":7062,"questionText":"What is the long-term outlook for  hidradenocarcinoma?","answerText":"Hidradenocarcinomas are known to be aggressive and have a high rate of growing again in the same area and metastasizing or spreading to other parts of the body, especially lymph nodes. With surgery alone, five year survival rate is less than 30%. The chance of the tumor returning after surgery is as high as 50%. &nbsp;It is unclear if the addition of radiation therapy, chemotherapy or targeted therapies improves the long term outlook.[12092][12093]<br />\r\n<br />\r\nFactors which seem to predict a better outcome include finding the cancer at an early stage and the ability to completely surgically remove the tumor. Prognosis is also better for younger individuals and those in good health. &nbsp;Tumors which do not respond to treatment have a poorer outlook, while the outlook for recurrent tumors is difficult to predict.[12092][12093]","dateModified":"2016-08-24T22:29:00","resourceClassificationName":"Prognosis","references":[{"referenceId":12093,"authors":"Soni A, Bansal N, Kaushal V, and Chauhan AK","articleTitle":"Current management approach to hidradenocarcinoma: a comprehensive review of the literature","bookWebsiteJournalTitle":"Ecancermedicalscience","date":"March 19 2015","volume":"9","pages":"517","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370612","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12094,"authors":"Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, and Joseph RW","articleTitle":"Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature","bookWebsiteJournalTitle":"Rare Tumors","date":"February 25 2015","volume":"7(1)","pages":"5719","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387361","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":33007,"abbreviatedInquiry":"I was recently diagnosed with hidradenocarcinoma in the same location where I&nbsp;previously had a basal cell carcinoma&nbsp;six years ago.&nbsp; Though I had surgery to remove the hidradenocarcinoma, the margins were not clear.&nbsp; I have been told that radiation is not an option.&nbsp; I would like information about treatment for this condition and which doctors could treat me.","caseQuestions":[{"questionId":5663,"questionText":"How might hidradenocarcinoma be treated?","answerText":"Because hidradenocarcinoma is quite rare, there are no established guidelines for treatment. &nbsp; The most accepted form of treatment is <a href=\"http://www.cancer.gov/dictionary?CdrID=446983\" target=\"_blank\">wide local excision</a>&nbsp;of the tumor, but due to the high risk that the tumor will grow back and frequent <a href=\"http://www.cancer.gov/types/metastatic-cancer\" target=\"_blank\">metastasis</a> to nearby <a href=\"http://www.cancer.gov/dictionary?CdrID=45762\" target=\"_blank\">lymph nodes</a> and other parts of the body, some doctors also suggest&nbsp;<a href=\"https://medlineplus.gov/radiationtherapy.html\" target=\"_blank\">radiation therapy</a> and/or&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/cancerchemotherapy.html\" target=\"_blank\">chemotherapy</a>&nbsp;after surgery.[12092][12093] &nbsp; <br />\r\n<br />\r\nNewer targeted therapies like&nbsp;<a href=\"http://www.cancer.gov/about-cancer/treatment/drugs/trastuzumab\" target=\"_blank\">trastuzumab</a>,&nbsp;<a href=\"https://www.drugs.com/drug-class/egfr-inhibitors.html\" target=\"_blank\">epidermal growth factor receptor (EGFR) inhibitors</a>, PI3K/Akt/mTOR pathway inhibitors (targets a pathway believed to be involved in controlling cell growth and division), hormonal agents like&nbsp;<a href=\"http://www.dermnetnz.org/topics/anti-androgen-therapy/\" target=\"_blank\">antiandrogens</a>, and electrochemotherapy (the use of electrical pulses to help get the chemo drugs into the cancer cells) may also be offered. &nbsp;Most of these therapies have only been reported in isolated case reports and often with conflicting results. Therefore it is difficult to determine which therapy or combination of therapies are the best treatment option. Options are usually determined by the size and location of the cancer and the extent to which cancer cells may have spread to nearby tissues.. &nbsp;Many researchers are hoping if there is a better understanding of the molecular genetic changes which happen in the cells of hidradenocarcinoma, the use of targeted therapies will improve long term prognosis.[12092][12093] &nbsp;","dateModified":"2016-08-24T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":12092,"authors":"","articleTitle":"Hidradenocarcinoma of Skin","bookWebsiteJournalTitle":"DoveMed","date":"January 7 2016","volume":"","pages":"","url":"http://www.dovemed.com/diseases-conditions/hidradenocarcinoma-skin","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12093,"authors":"Soni A, Bansal N, Kaushal V, and Chauhan AK","articleTitle":"Current management approach to hidradenocarcinoma: a comprehensive review of the literature","bookWebsiteJournalTitle":"Ecancermedicalscience","date":"March 19 2015","volume":"9","pages":"517","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370612","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Hidradenocarcinoma"}